#New Zealand #Auckland #Aroa Biosurgery #Endoform #Mölnlycke Healthcare

Aroa Biosurgery and Mölnlycke Join Forces for Enhanced Wound Care Access

Aroa Biosurgery Limited, a New Zealand-based company specializing in soft tissue regeneration, recently announced a strategic alliance with Mölnlycke Healthcare US. This partnership, effective from October 16, 2026, aims to improve the availability of Endoform™, a product designed for the management of acute and chronic wounds, across post-acute settings in the U.S.

The collaboration will leverage Aroa's groundbreaking AROA ECM™ technology alongside Mölnlycke's extensive expertise in wound care and established commercial presence. This agreement highlights a mutual goal of efficiently expanding the reach of Endoform to healthcare providers and patients alike.

Brian Ward, the founder and CEO of Aroa Biosurgery, expressed enthusiasm about the partnership, emphasizing Mölnlycke's reputation for excellence in the advanced wound care sector. He stated, "Mölnlycke's profound knowledge in this field provides a robust platform to enhance Endoform's accessibility to clinicians and patients, enriching patient care outcomes."

Mölnlycke’s VP for Americas, Craig Kennedy, echoed this sentiment, noting the importance of innovation and collaboration in advancing clinical practices. He remarked, “By integrating Endoform into our advanced wound dressing portfolio, we are broadening the range of solutions available to healthcare providers, addressing diverse patient needs effectively.”

Under this exclusive agreement, Aroa will retain ownership of the Endoform product and the proprietary AROA ECM technology. Aroa is set to continue its responsibilities for manufacturing, distribution, and supply logistics of Endoform. Additionally, this partnership allows Aroa to concentrate its efforts on the growth of its Myriad™ product in surgical contexts and capitalize on the potential of Symphony™ for outpatient wound care.

Importantly, the partnership specifically targets the distribution of Endoform in U.S. post-acute settings, with no changes anticipated for Aroa’s other product lines or international distribution agreements. The financial outlook for Aroa remains solid, with estimates projecting NZ$115 to NZ$125 million in total revenue for FY27, along with an expected normalized EBITDA of NZ$8 to NZ$11 million.

About Endoform

Endoform products are designed as extracellular matrix materials, ideal for managing wounds in both acute and chronic scenarios within outpatient and post-acute settings. The unique formulation aims to enhance healing by providing a supportive environment conducive to tissue regeneration.

About Aroa Biosurgery

Aroa Biosurgery Limited is dedicated to developing state-of-the-art products for dealing with complex wounds and facilitating soft tissue reconstruction. Through the integration of proprietary AROA ECM technology, Aroa is at the forefront of innovative solutions in biosurgery. For more details regarding their offerings, visit aroa.com.

About Mölnlycke

Established in 1849, Mölnlycke Health Care is a leading medical technology company specializing in advanced solutions for both wound care and surgical settings. Their products help healthcare practitioners globally to enhance patient care, with everyday applications in over 100 countries. For further information, visit molnlycke.com.

In summary, this alliance marks a significant step forward in enhancing wound care solutions available in the U.S. As healthcare continues to evolve, such partnerships underscore the essential role of collaboration in realizing innovations that improve patient outcomes.